| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥165.6B | ¥143.3B | +15.5% |
| Operating Income / Operating Profit | ¥11.5B | ¥10.3B | +11.7% |
| Equity-method Investment Income (Loss) | - | - | - |
| Ordinary Income | ¥10.8B | ¥10.4B | +3.6% |
| Net Income / Net Profit | ¥5.9B | ¥5.0B | +17.6% |
| ROE | 2.1% | 1.8% | - |
For Q1 of the fiscal year ending February 2026, Revenue was ¥165.6B (YoY +¥22.3B, +15.5%), Operating Income was ¥11.5B (YoY +¥1.2B, +11.7%), Ordinary Income was ¥10.8B (YoY +¥0.4B, +3.6%), and Net Income attributable to owners of the parent was ¥5.9B (YoY +¥0.9B, +17.6%). While both revenue and profit increased, the operating margin contracted by 24bp to 7.0%, and the growth rate of Ordinary Income (+3.6%) lagged Operating Income growth (+11.7%). Progress against the full-year plan (Revenue ¥680.0B, Operating Income ¥34.0B, Ordinary Income ¥33.0B) stands at Revenue 24.4%, Operating Income 33.9%, Ordinary Income 32.7%, and Net Income 25.0%, indicating an advanced start on the profit front.
[Revenue] Revenue of ¥165.6B was up +15.5% YoY, driven by double-digit growth in Chemicals (+32.5%) and HBC & Food (+48.9%). By segment, HBC & Food was the largest at ¥55.0B (33.2% of sales), contributing an increase of ¥18.0B YoY. Chemicals recorded ¥29.3B (17.7%) with an increase of ¥7.2B, and Pharmaceuticals ¥30.6B (18.5%) with a slight increase of ¥1.5B. Conversely, Fine Chemicals declined to ¥52.4B (31.6%), down ¥5.0B (-8.8%), partially offsetting overall growth. Gross profit was ¥58.9B (gross margin 35.6%), approximately 40bp improvement from ¥50.5B (35.2%) in the prior year period, reflecting pass-through pricing or product-mix improvements.
[Profitability] Operating Income of ¥11.5B increased +11.7% YoY, but SG&A rose to ¥47.4B (SG&A ratio 28.6%) from ¥40.1B (28.0%) in the prior year period, an increase of about 60bp, which pressured operating margins relative to sales growth. By segment, Chemicals delivered the highest profitability with Operating Income of ¥3.8B (margin 12.8%), achieving a large YoY increase of +178.5%. HBC & Food posted ¥2.6B (margin 4.8%, +27.4%), Pharmaceuticals ¥2.6B (margin 8.5%, -26.8%), and Fine Chemicals ¥2.1B (margin 4.1%, -41.4%), showing mixed outcomes. Non-operating income was ¥0.8B and non-operating expenses ¥1.5B; interest expense of ¥0.7B (up from ¥0.3B) weighed on Ordinary Income, causing a larger drop from Operating Income to Ordinary Income. Extraordinary items included impairment losses of ¥0.7B (same as prior year), and gains on sale of investment securities of ¥0.1B recorded in the prior year were absent this period, resulting in Pre-tax Income of ¥10.8B. Income taxes were high at ¥4.9B (effective tax rate 45.4%), substantially compressing Net Income to ¥5.9B. In summary, revenue gains in HBC & Food and Chemicals supported overall performance, and higher profitability in Chemicals bolstered profits, but declines in Fine Chemicals and a high tax burden diluted margins in this revenue-and-profit-increasing result.
HBC & Food achieved Revenue ¥55.0B (YoY +48.9%) and Operating Income ¥2.6B (YoY +27.4%, margin 4.8%), acting as the primary driver of company-wide revenue growth. Chemicals reported Revenue ¥29.3B (YoY +32.5%) and Operating Income ¥3.8B (YoY +178.5%, margin 12.8%), boasting the highest margins and contributing the largest absolute profit. Pharmaceuticals recorded Revenue ¥30.6B (YoY +5.0%) and Operating Income ¥2.6B (YoY -26.8%, margin 8.5%), representing revenue growth but profit decline with margin down from 12.6% in the prior year. Fine Chemicals showed notable declines with Revenue ¥52.4B (YoY -8.8%) and Operating Income ¥2.1B (YoY -41.4%, margin 4.1%), a deterioration of 2.3pt from 6.4% the prior year, contributing to the company-wide margin decline. Other recorded Revenue ¥0.2B and Operating loss ¥0.8B, widening deficits. While Chemicals’ high profitability and HBC & Food’s scale expansion drive the company, turnaround of Fine Chemicals remains a near-term challenge.
[Profitability] Operating margin was 7.0%, down 24bp from 7.2% in the prior year period; Net margin was 3.6%, a marginal improvement from 3.5% prior. ROE was 2.1% (annualized), at a low level with significant room to improve capital efficiency. Gross margin at 35.6% improved +40bp YoY, reflecting pass-through pricing and product-mix benefits, while SG&A ratio rose to 28.6% (+60bp YoY), pressuring operating margins. [Cash Quality] Interest coverage (Operating Income / Interest Expense) was 17.7x, indicating sufficient interest-bearing capacity. Working capital efficiency is poor: DSO 371 days and DIO 314 days are prolonged, with Accounts Receivable at ¥168.2B and Inventory at ¥91.6B representing 35.5% of Total Assets ¥733.1B. Cash Conversion Cycle (CCC) is an extremely long 531 days, indicating lengthy cash realization from sales. [Investment Efficiency] Total Asset Turnover was 0.23x (annualized approx. 0.9x) and ROIC-equivalent (Operating Income / Total Assets) remained at 1.6%. Goodwill stood at ¥46.5B (16.7% of Net Assets) and intangible assets at ¥74.1B (10.1% of Total Assets), indicating a material share of M&A-derived assets. [Financial Soundness] Equity Ratio was 38.0%, improved from 36.3% at prior fiscal year-end. Interest-bearing debt totaled ¥219.4B (short-term borrowings ¥121.9B, long-term borrowings ¥97.5B), with long-term borrowings up ¥35.0B YoY (+56.1%) and short-term borrowings down ¥40.1B (-24.7%). Short-term liability ratio remains high at 55.5%, leaving sensitivity to refinancing risk. Debt/Equity ratio was 0.79x, Net D/E ratio 0.47x, Current Ratio 141.7%, and Quick Ratio 112.9%, satisfying short-term liquidity benchmarks. Cash and deposits were ¥84.7B, and Cash/Short-term Debt coverage was 0.69x, indicating limited liquidity buffer.
As the cash flow statement is not disclosed, funding movements are analyzed from balance sheet changes. Cash and deposits were ¥84.7B, down ¥17.2B from ¥101.9B at prior fiscal year-end. During this period, short-term borrowings decreased by ¥40.1B while long-term borrowings increased by ¥35.0B, extending maturities by shifting short-term debt to long-term and net compressing interest-bearing debt by ¥5.1B. Accounts receivable were ¥168.2B, down ¥20.0B from year-end, but inventory increased to ¥91.6B (+¥12.1B), indicating part of working capital is tied up in inventory. Accounts payable were ¥91.8B, down ¥3.7B from year-end, reflecting progress in supplier payments. The reduction in receivables is a cash inflow factor, but inventory increases offset this; the primary cause of cash decline appears to be repayment of short-term borrowings. Property, plant and equipment were ¥135.8B, a slight increase of ¥2.9B YoY, indicating no major capex. Non-operating income of ¥0.8B is minor (~0.5% of Revenue), and most profits are generated from operating activities. Interest expense of ¥0.7B doubled from ¥0.3B, implying rising average cost of interest-bearing debt. Poor working capital efficiency (DSO 371 days, DIO 314 days, CCC 531 days) constrains cash generation; accelerating receivables collection and reducing inventory are key to improving future free cash flow.
Non-operating income of ¥0.8B is minor at 0.5% of Revenue ¥165.6B, comprising interest and dividends received ¥0.3B, foreign exchange gains ¥0.0B, and other ¥0.5B. Equity-method investment income was ¥0.0B, indicating limited contribution from affiliates. Of non-operating expenses ¥1.5B, interest expense ¥0.7B (¥0.3B prior) was the largest item, and rising financing costs pressured Ordinary Income. Extraordinary items included impairment losses of ¥0.7B (Fine Chemicals segment); the same amount was recorded in the prior year, suggesting a continuing one-off factor in asset optimization. Prior year included gains on sale of investment securities ¥0.1B and gains on sale of fixed assets ¥0.0B, which were absent this period, and the drop in extraordinary gains is a factor in confirming recurring earnings power. The effective tax rate was 45.4% (Income taxes ¥4.9B / Pre-tax Income ¥10.8B), high and driving a large decline from Ordinary Income ¥10.8B to Net Income ¥5.9B. Comprehensive income was ¥8.5B (Net Income ¥5.9B + Other Comprehensive Income ¥2.6B); other comprehensive income comprised valuation differences on available-for-sale securities ¥2.2B, foreign currency translation adjustments ¥0.6B, and actuarial differences on retirement benefits -¥0.2B, with valuation gains on financial assets producing comprehensive income exceeding net income. On an accrual basis, long DSO (371 days) and long DIO (314 days) indicate a substantial lag between revenue recognition and cash inflows, producing a significant divergence between profit recognition and cash collection. Prolonged working capital rotation suggests relaxation of receivables terms or inventory buildup, which could lead to future impairment or discounting risk. Overall, recurring earnings are generated from operating activities with limited one-off factors, but high tax burden and deteriorating working capital efficiency dilute cash-based earnings quality.
Full-year plan remains unchanged at Revenue ¥680.0B (YoY +8.4%), Operating Income ¥34.0B (YoY +12.7%), Ordinary Income ¥33.0B (YoY +13.4%), and Net Income attributable to owners of the parent ¥23.5B (forecast EPS ¥58.22). Q1 progress rates were Revenue 24.4% (near standard 25%), Operating Income 33.9% (standard 25%: +8.9pt ahead), Ordinary Income 32.7% (standard 25%: +7.7pt ahead), and Net Income 25.0% (in line with standard). The advanced progress in Operating and Ordinary Income is attributable to high profitability in the Chemicals segment (Operating margin 12.8%, YoY +178.5%) and some timing differences in expenses (SG&A and R&D skewed to later periods). Since Revenue progress is near standard, seasonal and segment-mix effects likely favored margins in the first half. No revisions to the full-year plan were made, and management maintains a conservative outlook despite the strong first-half start.
Annual dividend forecast remains at ¥9.0 per share, implying a Payout Ratio of approximately 15.5% against forecast EPS ¥58.22, a conservative level. Retained earnings at the end of Q1 were ¥138.8B, up ¥2.2B from prior fiscal year-end, indicating steady internal reserves accumulation. No disclosure of dividends paid in the quarter has been made; a single year-end dividend is assumed. No share buybacks were disclosed, indicating a dividend-centric shareholder return policy. The Payout Ratio 15.5% is based on full-year forecasts; annualizing Q1 Net Income ¥5.9B yields ¥23.6B, roughly in line with the full-year forecast ¥23.5B. Given profit progress is advanced, the dividend level likely incorporates risk of margin decline in the second half. With Cash and deposits ¥84.7B and the Operating Cash Flow quality flag (CCC 531 days), durability of the dividend source is acceptable, but working capital efficiency improvement is essential to expand dividend capacity.
Working Capital Efficiency Deterioration Risk: DSO 371 days, DIO 314 days, and CCC 531 days are extremely prolonged, causing a significant lag in cash realization relative to revenue growth. Accounts receivable ¥168.2B and inventory ¥91.6B comprise 35.5% of Total Assets; if collection delays or inventory obsolescence/impairment materialize, operating cash flow deterioration and asset quality deterioration could follow. The inventory increase (¥12.1B YoY) needs to be assessed as strategic build for demand or as buildup; monitoring quarterly inventory turnover and sales growth trends is necessary.
Refinancing Risk: Of interest-bearing debt ¥219.4B, short-term borrowings ¥121.9B account for 55.5%, creating a material maturity mismatch. Long-term borrowings increased to ¥97.5B (+56.1% YoY) partially extending duration, but short-term dependence remains high. In a rising interest-rate environment, funding cost increases and adverse refinancing terms are risks. Interest expense increased to ¥0.7B from ¥0.3B, and rising average funding costs are compressing ordinary profit margin (6.5%). Cash and deposits ¥84.7B cover 69.5% of short-term borrowings, but significant working capital needs limit the buffer for sudden funding demands.
Inter-segment Profitability Gaps and Mix Risk: Profitability gap between Chemicals (margin 12.8%) and HBC & Food (margin 4.8%) is large, and the rapid expansion of HBC & Food (YoY +48.9%) dilutes company-wide operating margin. Fine Chemicals deteriorated to margin 4.1% from 6.4% prior and, with revenue -8.8% and profit -41.4%, could become a drag if the trend continues. Pharmaceuticals margin also declined to 8.5% from 12.6%. The trajectory of company-wide margins depends on segment-mix and each business’s recovery in profitability. Continued high profitability in Chemicals is assumed; if raw material prices or supply-demand conditions change and margins decline, company profits would be significantly impacted.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 7.0% | – | – |
| Net Margin | 3.6% | 7.4% (6.8%–7.9%) | -3.8pt |
Net margin trails the industry median by 3.8pt, with high tax burden and deteriorating working capital efficiency depressing profitability relative to peers.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 15.5% | 3.8% (0.9%–6.4%) | +11.7pt |
Revenue growth exceeds the industry median by 11.7pt, showing strong growth driven by double-digit expansion in HBC & Food and Chemicals.
※ Source: Company compilation
Sustainability of Revenue Growth and Advanced Profit Progress: Q1 achieved double-digit Revenue growth of +15.5% and Operating Income progress of 33.9%, ahead of schedule. Chemicals’ high profitability (margin 12.8%, YoY +178.5%) and HBC & Food’s scale expansion (Revenue +48.9%) drove growth, but Operating margin contracted to 7.0% (-24bp YoY) with SG&A ratio up +60bp pressuring margins. The full-year plan is unchanged, indicating expectations of cost increases or seasonal margin decline in H2. Segment-wise, maintaining Chemicals’ high profitability and restoring Fine Chemicals’ margins are necessary for company-wide margin improvement. Whether the pattern of standard revenue progress but front-loaded profit progress persists will depend on H2 segment mix and expense trends.
Working Capital Efficiency and Cash Generation Improvement as Top Priorities: DSO 371 days, DIO 314 days, and CCC 531 days are extremely prolonged, and revenue growth is not translating to cash conversion. Accounts receivable ¥168.2B and inventory ¥91.6B represent 35.5% of Total Assets; working capital expansion constrains free cash flow. Cash and deposits fell ¥17.2B in Q1 primarily due to short-term borrowing repayments, while inventory increased ¥12.1B YoY, suggesting inventory build tied to sales growth is pressuring liquidity. If receivables collection accelerates and inventory turnover normalizes, operating cash flow could improve materially and reduce interest-bearing debt. Reducing short-term borrowing reliance (55.5%) and strengthening cash generation are directly linked to financial soundness and shareholder return capacity expansion.
This report is an AI-generated earnings analysis document produced by analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by the Company from public financial statements. Investment decisions should be made at your own responsibility and, where appropriate, after consulting a professional advisor.